N6, A Novel, Broad, Highly Potent HIV-specific Antibody

This is a new antibody coming out of NIAID’s intramural program. N6 has evolved a unique mode of binding that depends less on a variable area of the HIV envelope known as the V5 region and focuses more on conserved regions, which change relatively little among HIV strains. This allows N6 to tolerate changes in the HIV envelope, including the attachment of sugars in the V5 region, a major mechanism by which HIV develops resistance to other VRC01-class antibodies. N6 was shown in pre-clinical studies to neutralize 98 percent of HIV isolates tested.

Recombinant Sulfated HIV Envelope Protein and Methods for Making Protein

This technology comprises sulfated recombinant gp120 proteins and peptides. Also included are methods for producing sulfated recombinant gp120 proteins. The focus of this technology is on sulfation of two tyrosines in the V2 loop of the HIV major envelope glycoprotein, gp120, which increase the stability of gp120 and promote the synthesis of gp120 protein in its native "closed" conformation. Gp120 in its native form is highly sulfated; however, recombinant gp120 produced for vaccines or structural analyses typically display low levels of V2 tyrosine sulfation.

Broadly Neutralizing Human Anti-HIV Monoclonal Antibody 10E8 and Related Antibodies Capable of Neutralizing Most HIV-1 Strains

The uses for human anti-HIV monoclonal antibody 10E8 and its variants include passive immunization, therapeutic vaccination, and the development of vaccine immunogens. 10E8 is one of the most potent HIV-neutralizing antibodies isolated and it neutralizes up to 98% of diverse HIV-1 strains. 10E8 is specific to the membrane-proximal external region (MPER) of the HIV envelope protein gp41 and 10E8 is orthogonal to other anti-HIV antibodies. In combination with other antibodies 10E8 may provide an antibody response that neutralizes nearly all strains of HIV-1.

The Use of alpha-4 beta-7 integrin Inhibitors to Inhibit HIV Transmission and Infection

This invention involves the use of inhibitors of alpha-4 beta-7 (a4b7) integrin to inhibit HIV transmission/infection, as a prophylactic to inhibit onset of the acute stage of HIV infection or to treat HIV infection. The a4b7 integrin inhibitors were previously developed for use in other diseases, such as multiple sclerosis or inflammatory bowel disease.

NIAID License to BioNTech Facilitated the Development of an mRNA Vaccine for SARS-CoV-2 (Comirnaty®)

LES logo

The LES Deal of Distinction award recognizes major business transactions involving licensing, that exemplify best practices and creativity to achieve strategic product development objectives, with a significant impact on advancing innovation in the industry sectors that comprise LES which includes pharmaceutical and biomedical technology. This LES award specifically recognizes two deals that were negotiated by NIAID technology transfer officers with an array of partners in industry and academic institutions, or Industry University Government Interface (IUGI) sector.

FDA-Approved RSV Vaccine Based on NIAID’s F Protein Technology

FLC logo

THE PROBLEM: Respiratory syncytial virus (RSV) is a common virus that typically causes mild, cold-like symptoms — but it can be deadly to older adults, young children and people with chronic heart or lung disease or weakened immune systems. Each year in the U.S., 60,000 to 160,000 adults 65 years and older are hospitalized, and up to 10,000 people die each year from RSV infection, according to the Centers for Disease Control and Prevention.
 

Changing Lives in PASLI/APDS Patients, Disease Discovery and Treatment.

FLC logo

THE PROBLEM: APDS (activated PI3 kinase delta syndrome) — also known as PASLI (p110 delta-activating mutation causing senescent T cells, lymphadenopathy and immunodeficiency) disease — is a rare disorder that severely impairs the immune system’s ability to fight bacterial and viral infections, making patients susceptible to severe and recurrent infections, lymphoma, autoimmune diseases and other health issues. This disease is estimated to affect up to two people per million, and it can only be cured via bone marrow transplant.

Subscribe to NIAID